Viva Biotech completes HKD 1.24 million share buyback; total repurchases climb to 29.79 million shares

Bulletin Express06-18

Viva Biotech Holdings disclosed a Next Day Disclosure Return dated 18 June 2026, confirming an on-market repurchase of 1.10 million ordinary shares on 18 June at prices between HKD 1.12 and HKD 1.14 per share, for a total consideration of HKD 1.24 million. The volume-weighted average purchase price was approximately HKD 1.13 per share.

The transaction leaves the company’s issued share capital unchanged at 2.13 billion shares, as the repurchased stock has not yet been cancelled. Including this latest tranche, Viva Biotech has repurchased 29.79 million shares since the current mandate was approved on 12 June 2025, representing 1.40 % of the shares in issue on the mandate date.

All 29.79 million repurchased shares—acquired between 8 May and 18 June 2026—remain pending cancellation. The company is authorised to repurchase up to 212.84 million shares under the existing mandate, leaving a remaining capacity of about 183.05 million shares.

Under Hong Kong Stock Exchange rules, Viva Biotech is subject to a 30-day moratorium on issuing new shares following the 18 June repurchase, expiring on 18 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122488634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 18:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122488634","market":"hk","top_or_hot":-1,"title":"Viva Biotech completes HKD 1.24 million share buyback; total repurchases climb to 29.79 million shares","media":"Bulletin Express","content":"<p>Viva Biotech Holdings disclosed a Next Day Disclosure Return dated 18 June 2026, confirming an on-market repurchase of 1.10 million ordinary shares on 18 June at prices between HKD 1.12 and HKD 1.14 per share, for a total consideration of HKD 1.24 million. The volume-weighted average purchase price was approximately HKD 1.13 per share.</p>\n<p>The transaction leaves the company’s issued share capital unchanged at 2.13 billion shares, as the repurchased stock has not yet been cancelled. Including this latest tranche, Viva Biotech has repurchased 29.79 million shares since the current mandate was approved on 12 June 2025, representing 1.40 % of the shares in issue on the mandate date.</p>\n<p>All 29.79 million repurchased shares—acquired between 8 May and 18 June 2026—remain pending cancellation. The company is authorised to repurchase up to 212.84 million shares under the existing mandate, leaving a remaining capacity of about 183.05 million shares.</p>\n<p>Under Hong Kong Stock Exchange rules, Viva Biotech is subject to a 30-day moratorium on issuing new shares following the 18 June repurchase, expiring on 18 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech completes HKD 1.24 million share buyback; total repurchases climb to 29.79 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech completes HKD 1.24 million share buyback; total repurchases climb to 29.79 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-18 18:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings disclosed a Next Day Disclosure Return dated 18 June 2026, confirming an on-market repurchase of 1.10 million ordinary shares on 18 June at prices between HKD 1.12 and HKD 1.14 per share, for a total consideration of HKD 1.24 million. The volume-weighted average purchase price was approximately HKD 1.13 per share.</p>\n<p>The transaction leaves the company’s issued share capital unchanged at 2.13 billion shares, as the repurchased stock has not yet been cancelled. Including this latest tranche, Viva Biotech has repurchased 29.79 million shares since the current mandate was approved on 12 June 2025, representing 1.40 % of the shares in issue on the mandate date.</p>\n<p>All 29.79 million repurchased shares—acquired between 8 May and 18 June 2026—remain pending cancellation. The company is authorised to repurchase up to 212.84 million shares under the existing mandate, leaving a remaining capacity of about 183.05 million shares.</p>\n<p>Under Hong Kong Stock Exchange rules, Viva Biotech is subject to a 30-day moratorium on issuing new shares following the 18 June repurchase, expiring on 18 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1122488634","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122488634","pubTimestamp":1781778341,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings disclosed a Next Day Disclosure Return dated 18 June 2026, confirming an on-market repurchase of 1.10 million ordinary shares on 18 June at prices between HKD 1.12 and HKD 1.14...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物完成124万港元股份回购；回购总量攀升至2979万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings disclosed a Next Day Disclosure Return dated 18 June 2026, confirming an on-market repurchase of 1.10 million ordinary shares on 18 June at prices between HKD 1.12 and HKD 1.14 per share, for a total consideration of HKD 1.24 million. The volume-weighted average purchase price was approximately HKD 1.13 per share.\nThe transaction leaves the company’s issued share capital unchanged at 2.13 billion shares, as the repurchased stock has not yet been cancelled. Including this latest tranche, Viva Biotech has repurchased 29.79 million shares since the current mandate was approved on 12 June 2025, representing 1.40 % of the shares in issue on the mandate date.\nAll 29.79 million repurchased shares—acquired between 8 May and 18 June 2026—remain pending cancellation. The company is authorised to repurchase up to 212.84 million shares under the existing mandate, leaving a remaining capacity of about 183.05 million shares.\nUnder Hong Kong Stock Exchange rules, Viva Biotech is subject to a 30-day moratorium on issuing new shares following the 18 June repurchase, expiring on 18 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122488634","isCrawlerRequest":true}